Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The Human Genome Project's promise for identifying cancer drug targets has not significantly boosted drug discovery productivity.
• Current drugs target a small fraction of human proteins, limiting the scope of genome-based strategies.
• Mechanistic targets, identified through empirical research in disease models, offer a wider range of druggable targets beyond the genome and epigenome.

Purpose of the Study:

• To explore emerging areas for novel drug target identification in cancer.
• To highlight the shift towards mechanistic targets for improved therapeutic development.
• To discuss potential combination therapies to combat cancer drug resistance.

Main Methods:

• Review of current drug discovery approaches and target identification strategies.
• Analysis of emerging therapeutic areas including tumor metabolism, protein turnover, protein-protein interactions, and DNA-related targets.
• Discussion of cancer cell heterogeneity and mechanisms of drug resistance.

Main Results:

• Mechanistic targets enable exploration beyond the genome and epigenome, expanding druggable target identification.
• Emerging areas like tumor metabolism (Warburg effect), E3 ubiquitin ligases, protein-protein interactions, and DNA structures offer promising therapeutic avenues.
• Cancer cells' genetic and phenotypic heterogeneity can lead to drug resistance through adaptive signaling pathways.

Conclusions:

• A paradigm shift towards mechanistic targets is advancing new therapeutic agents for cancer.
• Targeting novel pathways like tumor metabolism and protein turnover holds significant potential.
• Combination therapies involving targeted agents and cytotoxic drugs are crucial for overcoming cancer drug resistance and improving treatment outcomes.